Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Evolan Pharma AB
AB
Active
Org 5567189781
Svärdvägen 19, 182 33
Danderyd
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 2006 · 19 years old
30 employees
Monitor
Share
Sweden
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Evolan Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
341M
682M
1B
1B
669M
2021
737M
2022
949M
2023
1.0B
2024
1.2B
2025
EBITDA
SEK millions
710M
533M
355M
178M
0M
265M
2021
307M
+16%
2022
400M
+30%
2023
414M
+4%
2024
568M
+37%
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
668 681
736 919
948 637
1 002 613
1 186 466
Staff expenses
—
—
—
—
−38 216
EBITDA
265 027
306 627
400 047
414 457
567 678
Depreciation & amort.
−71 463
−76 884
−105 747
−80 681
−110 036
EBIT
193 564
229 743
294 300
333 776
457 641
Net financials
1 365
4 135
−6 768
−3 610
−642
Profit before tax
147 175
184 836
217 530
290 528
665 847
Tax
−30 230
−35 497
−58 825
−69 614
−138 885
Net profit
116 945
149 339
158 705
220 914
526 962
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
552 285
863 471
1 017 471
1 211 124
1 482 382
Equity
250 533
373 290
522 163
732 076
1 246 038
Long-term debt
985
78 734
0
0
—
Short-term debt
153 067
213 748
227 609
211 348
193 644
Total debt
154 052
292 482
227 609
211 348
193 644
Financial ratios
5-year trend
EBITDA margin
47.8%
This company
15.8%
Market median
+203% vs market
2021
2025
Equity ratio
84.1%
This company
38.2%
Market median
+120% vs market
2021
2025
Return on equity
42.3%
This company
18.4%
Market median
+130% vs market
2021
2025
Net profit margin
44.4%
This company
8.1%
Market median
+448% vs market
2021
2025
Asset turnover
0.80×
This company
1.12×
Market median
-29% vs market
2021
2025
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Evolan Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
